UBS Group’s Celyad Oncology SA American Depositary Shares CYAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-2,124
| Closed | -$2.04K | – | 10320 |
|
|
2023
Q1 | $2.04K | Sell |
2,124
-3,663
| -63% | -$4.15K | ﹤0.01% | 8601 |
|
|
2022
Q4 | $2.84K | Sell |
5,787
-2,919
| -34% | -$2.96K | ﹤0.01% | 9614 |
|
|
2022
Q3 | $12K | Buy |
8,706
+4,658
| +115% | +$8.57K | ﹤0.01% | 8235 |
|
|
2022
Q2 | $7K | Sell |
4,048
-6
| -0.1% | -$12 | ﹤0.01% | 8588 |
|
|
2022
Q1 | $10K | Buy |
4,054
+474
| +13% | +$1.45K | ﹤0.01% | 8480 |
|
|
2021
Q4 | $13K | Sell |
3,580
-812
| -18% | -$3.41K | ﹤0.01% | 8505 |
|
|
2021
Q3 | $18K | Buy |
4,392
+3,335
| +316% | +$14.6K | ﹤0.01% | 7307 |
|
|
2021
Q2 | $6K | Sell |
1,057
-835
| -44% | -$4.99K | ﹤0.01% | 8484 |
|
|
2021
Q1 | $14K | Buy |
1,892
+1,392
| +278% | +$10.9K | ﹤0.01% | 7696 |
|
|
2020
Q4 | $4K | Sell |
500
-209
| -29% | -$1.79K | ﹤0.01% | 7947 |
|
|
2020
Q3 | $7K | Sell |
709
-918
| -56% | -$9.25K | ﹤0.01% | 7159 |
|
|
2020
Q2 | $17K | Buy |
1,627
+527
| +48% | +$5.14K | ﹤0.01% | 6670 |
|
|
2020
Q1 | $8K | Sell |
1,100
-1,964
| -64% | -$18.7K | ﹤0.01% | 7101 |
|
|
2019
Q4 | $32K | Buy |
3,064
+2,166
| +241% | +$21.8K | ﹤0.01% | 6605 |
|
|
2019
Q3 | $9K | Buy |
898
+398
| +80% | +$4.92K | ﹤0.01% | 7237 |
|
|
2019
Q2 | $6K | Sell |
500
-362
| -42% | -$6.9K | ﹤0.01% | 7341 |
|
|
2019
Q1 | $17K | Sell |
862
-453
| -34% | -$9.7K | ﹤0.01% | 6449 |
|
|
2018
Q4 | $24K | Sell |
1,315
-503
| -28% | -$12.1K | ﹤0.01% | 6651 |
|
|
2018
Q3 | $48K | Sell |
1,818
-6
| -0.3% | -$176 | ﹤0.01% | 6193 |
|
|
2018
Q2 | $54K | Buy |
1,824
+351
| +24% | +$10.8K | ﹤0.01% | 5913 |
|
|
2018
Q1 | $50K | Buy |
1,473
+427
| +41% | +$17.8K | ﹤0.01% | 5714 |
|
|
2017
Q4 | $46K | Buy |
1,046
+173
| +20% | +$8.64K | ﹤0.01% | 5908 |
|
|
2017
Q3 | $49K | Sell |
873
-384
| -31% | -$17.2K | ﹤0.01% | 5812 |
|
|
2017
Q2 | $53K | Buy |
1,257
+846
| +206% | +$33.5K | ﹤0.01% | 5606 |
|
|
2017
Q1 | $11K | Buy |
411
+347
| +542% | +$7.55K | ﹤0.01% | 6569 |
|
|
2016
Q4 | $1K | Buy |
+64
| New | +$1.22K | ﹤0.01% | 7663 |
|
|
2016
Q3 | – | Sell |
-522
| Closed | -$13K | – | 8021 |
|
|
2016
Q2 | $13K | Sell |
522
-754
| -59% | -$35.9K | ﹤0.01% | 6636 |
|
|
2016
Q1 | $56K | Sell |
1,276
-1,744
| -58% | -$71.2K | ﹤0.01% | 5421 |
|
|
2015
Q4 | $165K | Buy |
3,020
+331
| +12% | +$14.6K | ﹤0.01% | 4822 |
|
|
2015
Q3 | $112K | Sell |
2,689
-102,409
| -97% | -$5.27M | ﹤0.01% | 5131 |
|
|
2015
Q2 | $5.47M | Buy |
+105,098
| New | +$5.65M | ﹤0.01% | 1991 |
|
Other funds holding CYAD
UBS Group's CYAD Position: Q2 2023 in Review
UBS Group sold out of Celyad Oncology SA American Depositary Shares (CYAD) in Q2 2023, closing a stake of 2,124 shares — an estimated $2.04K sold.
UBS Group first reported a position in CYAD in Q2 2015 and held it in 31 quarters. The position peaked at $5.47M in Q2 2015. 2 funds tracked by Wall St. Rank hold CYAD as of Q2 2023.
- UBS Group reported no remaining Celyad Oncology SA American Depositary Shares position as of Q2 2023 after selling out during the quarter.
- UBS Group sold 2,124 Celyad Oncology SA American Depositary Shares shares in Q2 2023, an estimated $2.04K.
- UBS Group first reported a position in Celyad Oncology SA American Depositary Shares in Q2 2015 and held it in 31 quarters.
- UBS Group's Celyad Oncology SA American Depositary Shares position peaked at $5.47M in Q2 2015.
- 2 funds tracked by Wall St. Rank held Celyad Oncology SA American Depositary Shares as of Q2 2023.
Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.